Cytokinetics

Cardiovascular Account Specialist - U.S. Sales, Newark, NJ

Remote

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
BiopharmaceuticalsIndustries

Position Overview

  • Location Type: Territory (Edison, NJ and New Brunswick, NJ)
  • Employment Type: Full-time
  • Salary: (Not provided in the text) This role is with Cytokinetics, a late-stage biopharmaceutical company focused on developing muscle activators and inhibitors for cardiovascular diseases. The Cardiovascular Account Specialist will be responsible for launching a novel cardiac myosin inhibitor for Hypertrophic Cardiomyopathy (HCM) within their territory, driving sales and building relationships with key stakeholders.

Requirements

  • Education: Bachelor’s Degree required
  • Experience: 5+ years of experience in biotech/pharma sales required
  • Territory Ownership: Experience as a rep with sole ownership of the territory is highly preferred
  • Preferred Experience:
    • Cardiology, rare disease, or specialty product experience
    • Specialty product launch experience

Responsibilities

  • Sales Performance: Deliver sales results and operate autonomously as the single point of accountability for the product launch within the territory.
  • Account Planning: Develop territory-specific account plans to identify, assess, and prioritize opportunities to meet customer needs.
  • Collaboration: Coordinate efforts with internal stakeholders (medical, payer, patient navigation/support) and external customers.
  • Subject Matter Expertise: Serve as a subject matter expert and resource to customers, providing clinically relevant disease and product information.
  • Demand Generation: Communicate approved resources (marketing materials, payer information, formulary coverage, patient support services, educational programs) to healthcare professionals (HCPs) to create demand for the product.
  • Strategic Thinking: Demonstrate strategic thinking and a proactive approach in supporting the company’s mission to address unmet patient needs.

Application Instructions

  • (Not provided in the text)

Company Information

  • Company: Cytokinetics
  • Industry: Specialty Cardiovascular Biopharmaceutical Company
  • Focus: Discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for cardiovascular diseases.
  • Core Values:
    • Patients are our North Star
    • Science is in our Soul
    • We > Me
    • Make it Happen

Skills

BiotechSales
PharmaSales
Cardiology
RareDisease
SpecialtyProductLaunch
AccountPlanning
StakeholderCoordination
ClinicalKnowledge
DemandGeneration
StrategicThinking

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

South San Francisco, CaliforniaHeadquarters
1998Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Risks

Increased competition could impact market share and profitability.
Potential delays in clinical trials could hinder drug commercialization.
Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

Differentiation

Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
The company has a robust pipeline including omecamtiv mecarbil and aficamten.
Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Upsides

Recent investments indicate strong interest in muscle activators and inhibitors.
Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

Land your dream remote job 3x faster with AI